Bavarian Nordic Awarded Contract Options from the U.S. Government for Production and Supply of Freeze-dried Smallpox/Mpox Vaccines
Bavarian Nordic A/S
Exercised options total USD 143.6 million
Secures manufacturing and supply of freeze-dried JYNNEOS® to the U.S. in 2026
COPENHAGEN, Denmark, May 6, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (HHS), has exercised additional options valued at USD 143.6 million under the existing contract to supply a freeze-dried formulation of JYNNEOS® smallpox vaccine.
The options support the manufacturing and supply of freeze-dried JYNNEOS by conversion of bulk vaccine, previously manufactured under other contract options, as well as supplemental payments for all doses procured under the freeze-dried contract, triggered by the demonstration of an extended shelf-life. The supplemental payments will be invoiced pro rata with deliveries of the freeze-dried vaccines. Deliveries under the new contract options are planned for 2026.
Bavarian Nordic's financial guidance for 2025 remains unchanged at total revenues of DKK 5,700-6,700 million and an EBITDA margin of 26-30%. From the Public Preparedness business, revenue of DKK 3,000-4,000 million is still expected, of which DKK 2,650 million has been secured, which is an increase of DKK 150 million following exercise of the options.
Paul Chaplin, President & CEO of Bavarian Nordic, said: 'Following the recent FDA approval of the freeze-dried formulation of our smallpox/mpox vaccine, we applaud the U.S. government's steadfast commitment to improving national health security through the exercise of these options. The freeze-dried vaccine, with its improved shelf life, provides a significant contribution to securing the long-term availability of countermeasures to protect U.S citizens against life-threatening diseases.'
About our contracts with the U.S. government
Since 2003, Bavarian Nordic has worked with the U.S. government on the development, manufacturing and supply of a non-replicating smallpox vaccine to ensure all populations can be protected from smallpox and mpox, including people with weakened immune systems who are at high risk of adverse reactions to traditional smallpox vaccines, which are based on replicating vaccinia virus strains.
Approved by the FDA in 2019, JYNNEOS was the first smallpox vaccine successfully developed under Project BioShield, a program created by the U.S. Congress in 2004 to accelerate the research, development, procurement, and availability of medical countermeasures against biological, chemical, radiological, and nuclear (CBRN) threats through public-private partnerships.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Indianapolis Star
an hour ago
- Indianapolis Star
FDA: More cucumbers, ready-to-eat products recalled in growing salmonella outbreak
A Maryland food company has recalled specific salsa and cucumber products because they were made with cucumbers that are possibly contaminated with salmonella. TGD Cuts, LLC of Jessup, Maryland, is recalling some tub and tray products because they contained cucumbers from Boynton Beach, Florida-based Bedner Growers Inc., which have been linked to a salmonella outbreak. TGD Cuts distributed the affected products, which included salsas, sliced cucumbers and cucumber spears, to retail and foodservice locations in Maryland, Virginia, Pennsylvania, New Jersey, and North Carolina, according to the Food and Drug Administration (FDA). The products had use-by dates ranging from May 20 to May 28 and are unlikely to be in stores or being used. No illnesses have been reported in connection with the products, the FDA said. Egg recall: Brown eggs sold at some Walmart stores have salmonella risk The initial May 19 recall involved cucumbers sold directly to consumers at Bednar's Farm Fresh Market, according to notices published May 19 by the Centers for Disease Control and Prevention (CDC) and the FDA. Subsequent recalls have been announced by grocers such as Harris Teeter, Kroger and Walmart for repackaged cucumbers for resale under different brand names or those used in ready-to-eat products, including vegetable trays and salads. The cucumbers, distributed by Fresh Start Produce Sales of Delray, Florida, also led to Target recalling individual cucumbers on May 30, specifically cucumber two-packs and various prepared foods products. In addition to the growing cucumber-related recall, other products have been recalled recently for potential salmonella contamination. The FDA on May 28 upgraded a recall of tomatoes distributed in three southern states to a Class I recall, meaning consumption of the food could cause serious health complications or lead to death. Then, on June 6, the CDC and FDA linked brown eggs sold in nine states – including at some Walmart stores – to an ongoing Salmonella Enteritidis outbreak, in which 79 people have been sickened and at least 21 hospitalized. Customers who purchased any products from TGD Cuts should get rid of them or return them for a full refund. Here is the list of products recalled due to a possible salmonella risk. Salmonella poisoning causes about 1.35 million illnesses, 26,500 hospitalizations, and 420 deaths each year in the U.S., according to the CDC and FDA. Symptoms, which include diarrhea, fever and stomach cramps, will usually occur six hours to six days after exposure and may last up to seven days. Symptoms from severe infections may include aches, headaches, elevated fever, lethargy, rashes, and blood in urine or stool. Mike Snider is a reporter on USA TODAY's Trending team. You can follow him on Threads, Bluesky, X and email him at mikegsnider & @ & @mikesnider & msnider@
Yahoo
an hour ago
- Yahoo
Financial Experts: These Are the Top Mistakes Americans Make When Investing in the Stock Market
There's no reason you should lose money investing in stocks, considering that the markets always move higher over time. This decade alone, the S&P 500 has risen by about 88%. Just investing in an S&P 500 fund could have helped any investor generate solid profits. But a lot of investors still take a beating on Wall Street because they make common mistakes that can be easily avoided. Read Next: Check Out: Here are the top mistakes Americans make when investing in the stock market, according to three financial experts contacted by GOBankingRates. Also see the No. 1 mistake Americans make with their Roth IRAs, according to experts. Misjudging risk was cited by Christine Chase, vice president and financial consultant at Fidelity Investments. More precisely, she cited a tendency to misjudge risk tolerance, which means too many investors either take on too much risk or are too conservative. Both extremes can negatively impact your return. 'Excessive risk can lead to emotional decision-making and panic-selling during market downturns, while being too conservative may prevent your portfolio from growing enough to meet long-term goals or keep pace with inflation,' Chase said. To help manage risk and navigate the market's ups and downs, she recommended maintaining a well-diversified portfolio and working with a financial professional. Be Aware: Anthony Grosso, a New York-based financial strategist and mortgage loan originator, told GOBankingRates the biggest mistake he sees people make is 'blindly trusting the news' when investing. He learned this lesson himself as a younger investor. 'What I learned fast is that by the time something makes [it to the news], the market has already reacted,' Grosso said. 'The news isn't meant to educate — it's there to get clicks and views. They will spin a story, beat a topic to death until you're panicked or euphoric, and both of those times are when you make emotional decisions which are the worst ones.' If you do watch the news, he recommended doing so with a healthy dose of skepticism. 'Try to get reports of the actual data — not someone's opinion on the data,' Grosso said. 'Learn to make your own opinions and it will give you the confidence to have a plan and stick with it.' Not cutting losses is a mistake that happens a lot, according to Edward Corona, a Florida-based trader and publisher of The Options Oracle Newsletter. In fact, it happened to him early in his career. 'I'd hang onto trades way too long, convincing myself they'd bounce back,' Corona told GOBankingRates. 'I'd look at charts, squint real hard, and try to find a reason to stay in. You know the drill: 'It's just a dip,' or 'I'm down, but not that much…'' The problem, he said, is that small losses can 'turn into portfolio wreckers real fast' if you stay with a sinking stock too long. His suggestion is to have a plan in place before hitting the 'buy' button and sticking with that plan when an investment goes south. 'I'm going to have a predetermined 'stop loss' and 'take profit' level before I enter the trade, which would be based on a support level,' Corona said. 'If it breaks below that level, I will exit the trade and redeploy the capital elsewhere.' More From GOBankingRates The 10 Most Reliable SUVs of 2025 This article originally appeared on Financial Experts: These Are the Top Mistakes Americans Make When Investing in the Stock Market Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
San Francisco Chronicle
2 hours ago
- San Francisco Chronicle
New Alzheimer's blood tests make diagnosis easier — but they're not right for everyone
The number of Americans with Alzheimer's disease, the most common cause of dementia in the U.S., is projected to rise significantly in the coming decades. The devastating disease has no cure, but the past several years have brought promising developments in new drug therapies and blood tests that help doctors treat and diagnose the disease. Here's what to know about the blood tests that diagnose Alzheimer's, one of which got full FDA approval in May. How they work Several commercially available blood tests have become available the past few years, most recently from biotech company Fujirebio Diagnostics, which got full approval from the FDA last month. Each test measures slightly different things, but overall they look for abnormal levels of certain proteins — amyloid and tau — in the blood. The accumulation of amyloid and tau proteins in the brain, often called plaques, are hallmark signs of Alzheimer's. If someone has tau plaques in the brain, for instance, some of that will leak out of the brain into the blood, resulting in a blood test result showing higher than normal levels of tau. In patients with symptoms of cognitive impairment, the tests predict an Alzheimer's diagnosis with about 90% accuracy. Why they're important The blood tests are a notable development because they are less expensive and less invasive than other types of testing that doctors have long used to diagnose patients with Alzheimer's. One is a PET scan, which involves injecting a patient with a radioactive tracer that binds to amyloid or tau in the brain so the presence of the proteins can be seen in a scan. It can cost several thousand dollars, compared to several hundred dollars for a blood test. The other is a spinal tap, which is painful or uncomfortable for many people. This method measures different forms of amyloid and tau in the spinal fluid. 'Up until these blood tests came out, a physician was stuck doing a PET scan or spinal tap, so not great options,' said Dr. Frank Longo, a professor of neurology at Stanford Medicine. 'The big breakthrough is finding something to measure in the blood that's about 90% accurate of what's going on in the brain, about as accurate as spinal fluid or a PET scan.' Doctors use the blood test as part of a broader medical evaluation that also includes a patient history, neurological exam and other testing. The blood test can help rule out Alzheimer's as the cause of a patient's cognitive impairment and potentially avoid unnecessary further testing. If someone's blood test comes back normal, for example, they may not have to undergo the PET scan or spinal tap, and their doctor can look into other potential causes of the cognitive impairment. 'That's the biggest practical thing it's doing now,' Longo said. It's important to distinguish Alzheimer's from other types of dementia because there are Alzheimer's treatments that have come out the last few years that help slow the progression of Alzheimer's. But patients must be in relatively early stages of the disease, with mild impairment or mild dementia, to be eligible. Some of the therapies have significant side effects, so patients would not want to start them unless they knew it was Alzheimer's, and not something else, causing the dementia. They're not for everyone The tests are approved only for people who already have symptoms of cognitive impairment and are of a certain age — 55 and over or 60 and over, depending on the test. They are not approved for healthy adults with normal cognition who want to diagnose or rule out Alzheimer's, or who are simply curious if they are at risk for developing Alzheimer's. They must be ordered by a doctor. They're becoming more common, but may not be covered by insurance Some of the blood tests have been available for a year or two, Longo said, but they were under an earlier and more limited type of FDA approval, not the full approval that the agency granted last month to the Fujirebio test. So they are poised to become more common. 'A year ago, most of my colleagues and I were not ordering these,' Longo said. 'I'd say less than 5% or 10% of the time we were ordering these. Now people are starting to order them in symptomatic patients. It's not rare now. They're starting to be recognized more.' Some primary care doctors are starting to order the tests as well, said Dr. Armen Moughamian, medical director of Sutter Health's Ray Dolby Brain Center at CPMC in San Francisco. The center treats patients with memory disorders. 'It's definitely a minority, but I've been seeing it done,' he said. As with many new medical tests, insurers may not cover them yet, but that usually evolves over time. Full FDA approval may help make the case for the tests to be covered, Longo said. 'There is some uncertainty and lack of clarity about whether insurance and Medicare pay,' Moughamian said. 'That creates some hesitancy for providers to order it.' They may one day be used to screen and diagnose healthy people earlier In people with Alzheimer's, amyloid plaques begin to form in the brain as many as 20 years before they show symptoms. Right now, newer therapies for Alzheimer's — like lecanemab and donanemab, which slow the progression of the disease — are approved only for people with symptoms. Those symptoms are mild cognitive impairment or mild dementia, the early stages of symptomatic Alzheimer's. This means people who have not yet developed symptoms, but who have amyloid plaques in the brain, cannot get these treatments. So if a blood test could be used in pre-symptomatic people, it could mean better screening and earlier diagnosis to larger groups of people. 'What we want to push for is earlier diagnosis because new therapies are available when we catch people in earlier stages,' Moughamian said. Moughamian is leading two clinical trials that examine whether drugs that remove amyloid in the brain, donanemab and another drug remternetug, can work in people who have amyloid plaques but have not yet developed symptoms. They are using an Alzheimer's blood test to see whether patients are eligible for the trial.
